Laurus Labs Q4 FY26 Results: PAT Key Highlights | Pharmaceuticals and API Manufacturing
- April 30, 2026
- Posted by: Kashish Aggarwal
- Category: News
Laurus Labs announced its Q4 FY26 financial results on April 30, 2026, with results as per the official NSE and BSE exchange filing as the Pharmaceuticals and API Manufacturing company delivered its January to March 2026 quarter performance. Laurus Labs Q4 FY26 results are a closely watched data point for investors tracking the company’s earnings trajectory. This article covers the Laurus Labs Q4 FY26 financial highlights, performance analysis, FY26 business summary, management outlook, and investor FAQs on Laurus Labs Q4 results.
Laurus Labs Q4 FY26 Financial Highlights
Laurus Labs Limited announced its Q4 FY26 financial results on April 30, 2026. The Hyderabad-based pharma company is a leading manufacturer of Active Pharmaceutical Ingredients for anti-retroviral, oncology, and other therapeutic areas. Laurus Labs Q4 FY26 details are as per exchange filings.
| Metric | Q4 FY26 | Q4 FY25 | YoY Change |
|---|---|---|---|
| Revenue / Total Income | as per NSE/BSE exchange filing | Refer NSE/BSE filing | Grew YoY |
| PAT | as per NSE/BSE exchange filing | Refer NSE/BSE filing | Refer exchange filing |
| Full Year FY26 PAT | Refer annual filing | Refer filing | As reported |
| Dividend (FY26) | Not declared in Q4 announcement | Refer filing | FY26 final |
Also Read: Bhansali Engineering Polymers Q4 FY26 Results
Laurus Labs Q4 FY26 Performance Analysis
Laurus Labs Q4 FY26 performance was shaped by its API and finished dosage form businesses. The company’s anti-retroviral API segment remained a revenue anchor while the CDMO and synthesis business gained traction from global innovator partnerships in Laurus Labs Q4 FY26.
Laurus Labs Q4 FY26 CDMO revenues continued to build as the company scales its synthesis chemistry capabilities for global pharmaceutical companies. FY26 marked meaningful progress in the Laurus Labs CDMO segment, which commands higher margins than generic API manufacturing.
Laurus Labs Full Year FY26 Business Summary
FY26 was a year of business mix improvement for Laurus Labs, with CDMO growing as a share of revenue and the finished dosage form business scaling. The company’s Laurus Bio subsidiary also gained momentum in biotech APIs and fermentation-based products.
Laurus Labs Q4 FY26 Outlook and FY27 Priorities
Laurus Labs FY27 priorities include accelerating CDMO revenue, scaling the formulations business in the US and Africa, and growing Laurus Bio in biologics. The recovery in ARV demand from global health funding agencies also supports the API segment.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!
Conclusion
The Laurus Labs Q4 FY26 results provide investors with the company’s January to March 2026 quarter performance data. Laurus Labs Q4 FY26 PAT of as per NSE/BSE exchange filing reflects the company’s operational performance in the Pharmaceuticals and API Manufacturing sector. Investors tracking Laurus Labs Q4 results should review the complete audited financial statements on the NSE and BSE exchange filings before making any investment decision.
This article on Laurus Labs Q4 FY26 results is for informational and educational purposes only. It is not investment advice. Please consult a SEBI registered investment advisor before making any investment decision. Past performance is not indicative of future results.
Frequently Asked Questions FAQs on Laurus Labs Q4 FY26 Results
What were the Laurus Labs Q4 FY26 results?
Laurus Labs Q4 FY26 results were announced on April 30, 2026. The company reported PAT of as per NSE/BSE exchange filing for the January to March 2026 quarter. Laurus Labs Q4 FY26 details are available in the official NSE and BSE exchange filings.
What was Laurus Labs Q4 FY26 PAT?
Laurus Labs Q4 FY26 PAT stood at as per NSE/BSE exchange filing, as per the NSE/BSE exchange filing. The Laurus Labs Q4 results were announced on April 30, 2026, following the board of directors meeting.
What was Laurus Labs Q4 FY26 revenue?
Laurus Labs Q4 FY26 revenue was as per NSE/BSE exchange filing. Investors should refer to the complete NSE and BSE exchange filing for the audited revenue breakdown and segmental details for Laurus Labs Q4 FY26.
Did Laurus Labs declare a dividend after Q4 FY26 results?
No dividend was declared by Laurus Labs in the Q4 FY26 results announcement as per available information. Refer to official exchange filings for the latest update.
What is the outlook for Laurus Labs after Q4 FY26?
Laurus Labs FY27 priorities include accelerating CDMO revenue, scaling the formulations business in the US and Africa, and growing Laurus Bio in biologics. The recovery in ARV demand from global health funding agencies also supports the API segment. Investors should track management commentary and quarterly filings for updated guidance on Laurus Labs Q4 FY26 performance sustainability.
How did Laurus Labs Q4 FY26 compare to Q4 FY25?
Laurus Labs Q4 FY26 PAT of as per NSE/BSE exchange filing compared to the Q4 FY25 figure available in the company’s NSE and BSE exchange filing. The Laurus Labs Q4 year-on-year comparison is available in the official exchange filing. Refer to the audited Laurus Labs Q4 FY26 results for a complete year-on-year analysis.
What sector does Laurus Labs operate in and how did the sector perform in Q4 FY26?
Laurus Labs operates in the Pharmaceuticals and API Manufacturing sector in India. The Laurus Labs Q4 FY26 results reflect broader Pharmaceuticals and API Manufacturing sector trends for the January to March 2026 period. Investors should review sector-level data and management commentary to contextualise the Laurus Labs Q4 results within industry dynamics.
Is Laurus Labs a good investment after Q4 FY26 results?
Whether Laurus Labs is a good investment after the Laurus Labs Q4 FY26 results depends on individual financial goals, risk appetite, and investment horizon. The Laurus Labs Q4 results provide one data point. Always consult a SEBI registered financial advisor before making investment decisions on Laurus Labs or any other stock.
Recent Article
Max India Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Mawana Sugars Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Procter and Gamble Health Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Rama Phosphates Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Pudumjee Paper Products Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
